TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
OncoSil Medical Ltd ( (AU:OSL) ) has provided an update.
OncoSil Medical Limited announced that all resolutions at its Annual General Meeting were approved by poll. This outcome reflects strong shareholder support for the company’s strategic direction and operational decisions, potentially reinforcing its position in the medical device industry focused on cancer treatment.
The most recent analyst rating on (AU:OSL) stock is a Sell with a A$1.00 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
More about OncoSil Medical Ltd
OncoSil Medical Limited is a global medical device company specializing in Interventional Oncology, primarily focusing on localized treatments for unresectable locally advanced pancreatic cancer. The company has developed the OncoSil™ device, which uses Phosphorous-32 microparticles for targeted intratumoural placement, enhancing radiation delivery directly into tumors while minimizing exposure to surrounding organs. OncoSil™ has received CE Marking approval and is designated as a breakthrough device in Europe and the United States, with approval for sale in over 30 countries.
Average Trading Volume: 23,209
Technical Sentiment Signal: Sell
Current Market Cap: A$21.46M
Learn more about OSL stock on TipRanks’ Stock Analysis page.